80 related articles for article (PubMed ID: 12475446)
1. Significance of HER-2/neu expression in ovarian epithelial tumours.
Gao D; Lu Y; Lu Y; Wang Y; Zhang B; Wu B
Zhonghua Bing Li Xue Za Zhi; 2002 Jun; 31(3):268-70. PubMed ID: 12475446
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and significance of HER-2/neu amplification in epithelial ovarian cancer.
Wong YF; Cheung TH; Lam SK; Lu HJ; Zhuang YL; Chan MY; Chung TK
Gynecol Obstet Invest; 1995; 40(3):209-12. PubMed ID: 8529957
[TBL] [Abstract][Full Text] [Related]
3. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
[TBL] [Abstract][Full Text] [Related]
4. p53 and HER-2/neu overexpression in ovarian borderline tumors.
Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR
Gynecol Oncol; 1997 May; 65(2):218-24. PubMed ID: 9159328
[TBL] [Abstract][Full Text] [Related]
5. Expression of cell regulatory proteins in ovarian borderline tumors.
van Haaften-Day C; Russell P; Boyer CM; Kerns BJ; Wiener JR; Jensen DN; Bast RC; Hacker NF
Cancer; 1996 May; 77(10):2092-8. PubMed ID: 8640675
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma.
Tanabe H; Nishii H; Sakata A; Suzuki K; Mori Y; Shinozaki H; Watanabe A; Ochiai K; Yasuda M; Tanaka T
Gynecol Oncol; 2004 Sep; 94(3):735-9. PubMed ID: 15350366
[TBL] [Abstract][Full Text] [Related]
7. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.
Afify AM; Werness BA; Mark HF
Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445
[TBL] [Abstract][Full Text] [Related]
8. Effect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinoma.
Sasaki N; Kudoh K; Kita T; Tsuda H; Furuya K; Kikuchi Y
J Obstet Gynaecol Res; 2007 Feb; 33(1):17-23. PubMed ID: 17212661
[TBL] [Abstract][Full Text] [Related]
9. [Expression of telomerase and telomerase associated-regulation protein and proliferating cell nuclear antigen in ovarian epithelial tumors].
Gao DX; Lu Y; Lu YZ; Ma CH; Wang YP; Zhang B; Liao SL
Zhonghua Bing Li Xue Za Zhi; 2003 Aug; 32(4):319-22. PubMed ID: 14514375
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer.
Rubin SC; Finstad CL; Federici MG; Scheiner L; Lloyd KO; Hoskins WJ
Cancer; 1994 Mar; 73(5):1456-9. PubMed ID: 7906607
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis.
Rubin SC; Finstad CL; Wong GY; Almadrones L; Plante M; Lloyd KO
Am J Obstet Gynecol; 1993 Jan; 168(1 Pt 1):162-9. PubMed ID: 8093588
[TBL] [Abstract][Full Text] [Related]
12. The expression of immunohistochemical markers estrogen receptor, progesterone receptor, Her-2-neu, p53 and Ki-67 in epithelial ovarian tumors and its correlation with clinicopathologic variables.
Sylvia MT; Kumar S; Dasari P
Indian J Pathol Microbiol; 2012; 55(1):33-7. PubMed ID: 22499297
[TBL] [Abstract][Full Text] [Related]
13. p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.
Cabral VD; Cerski MR; Sa Brito IT; Kliemann LM
J Ovarian Res; 2016 Oct; 9(1):69. PubMed ID: 27770808
[TBL] [Abstract][Full Text] [Related]
14. NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms.
Kacinski BM; Mayer AG; King BL; Carter D; Chambers SK
Gynecol Oncol; 1992 Mar; 44(3):245-53. PubMed ID: 1347282
[TBL] [Abstract][Full Text] [Related]
15. The expression of HER-2/neu (c-erbB2), survivin and cycline D1 in serous ovarian neoplasms: their correlation with clinicopathological variables.
Turan G; Usta CS; Usta A; Kanter M; Tavli L; Karacan M; Celik C; Eser M
J Mol Histol; 2014 Dec; 45(6):679-87. PubMed ID: 25106503
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors.
Berchuck A; Kohler MF; Hopkins MP; Humphrey PA; Robboy SJ; Rodriguez GC; Soper JT; Clarke-Pearson DL; Bast RC
Gynecol Oncol; 1994 Feb; 52(2):232-6. PubMed ID: 7508877
[TBL] [Abstract][Full Text] [Related]
17. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
Riener EK; Arnold N; Kommoss F; Lauinger S; Pfisterer J
Gynecol Oncol; 2004 Oct; 95(1):89-94. PubMed ID: 15385115
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical study of the expression of HER-2/neu oncogene in ovarian lesions.
Marwah N; Bansal C; Gupta S; Singh S; Sapna ; Arora B
Indian J Pathol Microbiol; 2007 Jul; 50(3):489-92. PubMed ID: 17883115
[TBL] [Abstract][Full Text] [Related]
19. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
20. HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays.
Mayr D; Kanitz V; Amann G; Engel J; Burges A; Löhrs U; Diebold J
Histopathology; 2006 Jan; 48(2):149-56. PubMed ID: 16405663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
